![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GENENTECH SUBMITS SBLA FOR AVASTIN
GENENTECH SUBMITS SBLA FOR AVASTIN
December 19, 2005
Genentech has submitted a supplemental biologics license application (sBLA) with the FDA for Avastin (bevacizumab) in combination with 5-fluorouracil (5-FU)-based chemotherapy for patients with relapsed, metastatic colorectal cancer. Avastin is currently approved as a first-line treatment of metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy.
The sBLA submission is based on results of a randomized, controlled, multicenter Phase III trial of 829 patients with advanced or metastatic colorectal cancer (CRC) whose disease progressed following previous treatment with 5-FU and irinotecan-based chemotherapy. The study showed that patients who received Avastin plus the 5-FU-based chemotherapy regimen known as FOLFOX4 (oxaliplatin/5-FU/leucovorin) had a 25 percent reduction in the risk of death, the primary endpoint, which is equivalent to a 33 percent improvement in overall survival, compared to patients who received FOLFOX4 alone.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct